Additional work has shown CRIPTO correlated with efficacy of 1st/2nd generation EGFR-TKIs resistance in NSCLC and subsequent knockdown of CRIPTO in vitro restored sensitivity to erlotinib in patient-derived primary cells [161]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.